Bayesian analysis for cystic fibrosis risks in prenatal and carrier screening

被引:7
|
作者
Ogino, S
Wilson, RB
Gold, B
Hawley, P
Grody, WW
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[3] Univ Penn, Ctr Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[4] NCI, Human Genet Sect, Lab Genomic Divers, Frederick, MD 21701 USA
[5] Childrens Hosp, Dept Med, Boston, MA 02115 USA
[6] Univ Calif Los Angeles, Sch Med, Dept Pathol, Los Angeles, CA 90024 USA
[7] Univ Calif Los Angeles, Sch Med, Lab Med Human Genet & Pediat, Los Angeles, CA 90024 USA
关键词
CFTR; counseling; cystic fibrosis; probability; screening;
D O I
10.1097/01.GIM.0000139511.83336.8F
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose: Risk assessment is an essential component of genetic counseling and testing, and Bayesian analysis plays a central role in complex risk calculations. We previously developed generalizable Bayesian methods to calculate the autosomal recessive disease risk of a fetus when one or no mutation is detected, and another, independent risk factor is present. Our methods are particularly useful for calculating the CF disease risk for a fetus with echogenic bowel. In genetics practice, however, there are other scenarios for which our previous methods are inadequate. Methods and Results: We provide herein methods for calculating genetic risks in a variety of common clinical scenarios. These scenarios include the following: (1) different mutation panels that have been used for the parents and for a fetus; (2) genetic testing results available on the proband or other relatives, in addition to the consultand; (3) fetal ultrasound negative for echogenic bowel with a positive family history; and (4) a consultand with a mixed ethnic background. Conclusion: Our Bayesian methods have proven their versatility through application to many different common genetic counseling scenarios. These methods permit autosomal recessive disease and carrier probabilities to be calculated accurately, taking into account all relevant information. Our methods allow accurate genetic risk estimates for patients and their family members for CF or other autosomal recessive disorders.
引用
收藏
页码:439 / 449
页数:11
相关论文
共 50 条
  • [21] Is cystic fibrosis carrier screening cost effective?
    Wei, S.
    Quigg, M. H.
    Monaghan, K. G.
    COMMUNITY GENETICS, 2007, 10 (02) : 103 - 109
  • [22] Cost-effectiveness of carrier screening for cystic fibrosis in Australia
    Norman, Richard
    van Gool, Kees
    Hall, Jane
    Delatycki, Martin
    Massie, John
    JOURNAL OF CYSTIC FIBROSIS, 2012, 11 (04) : 281 - 287
  • [23] Issues in implementing prenatal screening for cystic fibrosis: Results of a working conference
    Haddow, JE
    Bradley, LA
    Palomaki, GE
    Doherty, RA
    Bernhardt, BA
    Brock, DJH
    Cheuvront, B
    Cunningham, GC
    Donnenfeld, AE
    Erickson, JL
    Erlich, HA
    Ferrie, RM
    FitzSimmons, SC
    Greene, MF
    Grody, WW
    Haddow, PK
    Harris, H
    Holmes, LB
    Howell, RR
    Katz, M
    Klinger, KW
    Kloza, EM
    LeFevre, ML
    Little, S
    Loeben, G
    McGovern, M
    Pyeritz, RE
    Rowley, PT
    Saiki, RK
    Short, MP
    Tabone, J
    Wald, NJ
    Wilker, NL
    Witt, DR
    GENETICS IN MEDICINE, 1999, 1 (04) : 129 - 135
  • [24] Cystic fibrosis testing 8 years on: Lessons learned from carrier screening and sequencing analysis
    Strom, Charles M.
    Crossley, Beryl
    Buller-Buerkle, Arlene
    Jarvis, Michael
    Quan, Franklin
    Peng, Mei
    Muralidharan, Kasinathan
    Pratt, Victoria
    Redman, Joy B.
    Sun, Weimin
    GENETICS IN MEDICINE, 2011, 13 (02) : 166 - 172
  • [25] COSTS AND BENEFITS OF PRENATAL SCREENING FOR CYSTIC-FIBROSIS
    GARBER, AM
    FENERTY, JP
    MEDICAL CARE, 1991, 29 (05) : 473 - 489
  • [26] Cystic fibrosis: selecting the prenatal screening strategy of choice
    Wald, NJ
    Morris, JK
    Rodeck, CH
    Haddow, JE
    Palomaki, GE
    PRENATAL DIAGNOSIS, 2003, 23 (06) : 474 - 483
  • [27] Cystic Fibrosis: A Look into the Future of Prenatal Screening and Therapy
    Nishida, Kevin
    Smith, Zachary
    Rana, Dane
    Palmer, Jereme
    Gallicano, G. Ian
    BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS, 2015, 105 (01) : 73 - 80
  • [28] Informing policy for the Australian context - Costs, outcomes and cost savings of prenatal carrier screening for cystic fibrosis
    Maxwell, Susannah
    Brameld, Kate
    Youngs, Leanne
    Geelhoed, Elizabeth
    O'Leary, Peter
    AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, 2010, 50 (01) : 51 - 59
  • [29] Preconception and prenatal cystic fibrosis carrier screening of African Americans reveals unanticipated frequencies for specific mutations
    Monaghan, KG
    Bluhm, D
    Phillips, M
    Feldman, GL
    GENETICS IN MEDICINE, 2004, 6 (03) : 141 - 144
  • [30] REPORTING THE RESULTS OF CYSTIC-FIBROSIS CARRIER SCREENING
    ASCH, DA
    PATTON, JP
    HERSHEY, JC
    MENNUTI, MT
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (01) : 1 - 6